An Update on Neurofibromatosis Type 1-Associated Gliomas

DOI Web Site 1 Citations
  • Mina Lobbous
    Division of Neuro Oncology, Department of Neurology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower suite 1020 Birmingham, Birmingham, AL 35294, USA
  • Joshua D. Bernstock
    Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
  • Elizabeth Coffee
    Division of Neuro Oncology, Department of Neurology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower suite 1020 Birmingham, Birmingham, AL 35294, USA
  • Gregory K. Friedman
    Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • Laura K Metrock
    Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • Gustavo Chagoya
    Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • Galal Elsayed
    Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • Ichiro Nakano
    Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • James R. Hackney
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • Bruce R. Korf
    Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
  • Louis B. Nabors
    Division of Neuro Oncology, Department of Neurology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower suite 1020 Birmingham, Birmingham, AL 35294, USA

Description

<jats:p>Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome that affects children and adults. Individuals with NF1 are at high risk for central nervous system neoplasms including gliomas. The purpose of this review is to discuss the spectrum of intracranial gliomas arising in individuals with NF1 with a focus on recent preclinical and clinical data. In this review, possible mechanisms of gliomagenesis are discussed, including the contribution of different signaling pathways and tumor microenvironment. Furthermore, we discuss the recent notable advances in the developing therapeutic landscape for NF1-associated gliomas including clinical trials and collaborative efforts.</jats:p>

Journal

  • Cancers

    Cancers 12 (1), 114-, 2020-01-01

    MDPI AG

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top